KRAS and colorectal carcinoma: The current treatment strategy for stage IV CRC includes the use of EGFR monoclonal antibodies (mAbs) in KRAS wild-type (KRAS-WT) tumors to suppress the EGFR-RAS signaling pathway that drives cellular survival and proliferation.